You are here: Industry Insights > bimekizumab

News List

Positive Top-Line Results from Bimekizumab Phase 3 Psoriatic Arthritis Study Demonstrated Significant Improvements in Joint and Skin Symptoms prnewswire
November 22, 2021
UCB, a global biopharmaceutical company, today announced positive top-line interim analysis results from the Phase 3 BE OPTIMAL study assessing the efficacy and safety of bimekizumab, a dual IL-17A and IL-17F inhibitor...
UCB’s BIMZELX (bimekizumab) receives expedited acceptance from Scottish Medicines Consortium (SMC) for the treatment of plaque psoriasis FirstWordPharma
November 10, 2021
Bimekizumab has received acceptance through the Scottish Medicines Consortium’s (SMC) fast- track process1
Interim trial data for UCB’s bimekizumab shows positive results pharmatimes
August 09, 2021
Interim data from a trial for UCB’s investigational IL-17A and IL-17F inhibitor bimekizumab in adults with moderate to severe plaque psoriasis have been presented during a presentation at the 2021 American Academy of Dermatology (AAD) summer meeting ...
NICE approves cost-comparison fast-track appraisal pilot europeanpharmaceuticalreview
August 03, 2021
A new approach to the cost-comparison fast-track appraisal process is being piloted this summer for the review of low-risk appraisals.
UCB’s bimekizumab issued NICE recommendation for severe plaque psoriasis pharmatimes
August 03, 2021
The National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Determination (FAD), recommending UCB’s bimekizumab as an option for the treatment of adults with severe plaque psoriasis.
UCB’s bimekizumab data in plaque psoriasis published in The Lancet pharmatimes
February 05, 2021
Data from two Phase III studies of UCB’s investigational treatment bimekizumab in moderate-to-severe plaque psoriasis have been published in The Lancet.
FDA and EMA accept regulatory submissions for UCB’s bimekizumab pharmatimes
September 27, 2020
The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both accepted marketing application submissions for UCB’s psoriasis treatment bimekizumab.